Decoding signaling and function of the orphan g protein-coupled receptor GPR17 with a small-molecule agonist

Science Signaling

Volumn 6, Issue 298, 2013, Pages

  Hennen, Stephanie ^a   Wang, Haibo ^b   Peters, Lucas ^a   Merten, Nicole ^a   Simon, Katharina ^a   Spinrath, Andreas ^a   Blättermann, Stefanie ^a   Akkari, Rhalid ^a   Schrage, Ramona ^a   Schröder, Ralf ^a   Schulz, Daniel ^a   Vermeiren, Celine ^c   Zimmermann, Katrin ^a   Kehraus, Stefan ^a   Drewke, Christel ^a   Pfeifer, Alexander ^a   König, Gabriele M ^a   Mohr, Klaus ^a   Gillard, Michel ^c   Müller, Christa E ^a   Lu, Q Richard ^b   Gomeza, Jesus ^a   Kostenis, Evi ^a   more..

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXY 4,6 DICHLORO 3 INDOLYL)PROPIONIC ACID; ADAPTOR PROTEIN; CALCIUM; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 17; GAVESTINEL; INOSITOL PHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROPROTECTIVE AGENT; SMALL MOLECULE AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL MATURATION; CONTROLLED STUDY; DEMYELINATING DISEASE; EMBRYO; HUMAN; HUMAN CELL; MOUSE; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELINATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL;

ANIMALS; ARRESTINS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CHO CELLS; CHROMONES; COS CELLS; CRICETINAE; CRICETULUS; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, KNOCKOUT; MOLECULAR STRUCTURE; NERVE TISSUE PROTEINS; OLIGODENDROGLIA; PROPIONATES; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STEM CELLS;

EID: 84886745200     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004350     Document Type: Article

References (71)

1. V. Siffrin, J. Vogt, H. Radbruch, R. Nitsch, F. Zipp, Multiple sclerosis - Candidate mechanisms underlying CNS atrophy. Trends Neurosci. 33, 202-210 (2010).
2. R. J. M. Franklin, C. Ffrench-Constant, Remyelination in the CNS: From biology to therapy. Nat. Rev. Neurosci. 9, 839-855 (2008).
3. S. P. J. Fancy, J. R. Chan, S. E. Baranzini, R. J. M. Franklin, D. H. Rowitch, Myelin regeneration: A recapitulation of development? Annu. Rev. Neurosci. 34, 21-43 (2011).
4. O. Aktas, B. Kieseier, H.-P. Hartung, Neuroprotection, regeneration and immunomodulation: Broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 33, 140-152 (2010).
5. P. K. Stys, G. W. Zamponi, J. van Minnen, J. J. G. Geurts, Will the real multiple sclerosis please stand up? Nat. Rev. Neurosci. 13, 507-514 (2012).
6. R. S. Lopez-Diego, H. L. Weiner, Novel therapeutic strategies for multiple sclerosis - A multifaceted adversary. Nat. Rev. Drug Discov. 7, 909-925 (2008).
7. H.-P. Hartung, O. Aktas, Evolution of multiple sclerosis treatment: Next generation therapies meet next generation efficacy criteria. Lancet Neurol. 10, 293-295 (2011).
8. D. Kremer, O. Aktas, H.-P. Hartung, P. Küry, The complex world of oligodendroglial differentiation inhibitors. Ann. Neurol. 69, 602-618 (2011).
9. T. Kuhlmann, V. Miron, Q. Cui, Q. Cuo, C. Wegner, J. Antel, W. Brück, Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131, 1749-1758 (2008).
10. S. Mi, R. H. Miller, X. Lee, M. L. Scott, S. Shulag-Morskaya, Z. Shao, J. Chang, G. Thill, M. Levesque, M. Zhang, C. Hession, D. Sah, B. Trapp, Z. He, V. Jung, J. M. McCoy, R. B. Pepinsky, LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 8, 745-751 (2005).
11. S. Mi, B. Hu, K. Hahm, Y. Luo, E. S. Kam Hui, Q. Yuan, W. M. Wong, L. Wang, H. Su, T.-H. Chu, J. Guo, W. Zhang, K.-F. So, B. Pepinsky, Z. Shao, C. Graff, E. Garber, V. Jung, E. X. Wu, W. Wu, LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 13, 1228-1233 (2007).
12. M. Rask-Andersen, M. S. Almén, H. B. Schiöth, Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579-590 (2011).
13. J. P. Overington, B. Al-Lazikani, A. L. Hopkins, How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996 (2006).
14. P. Ciana, M. Fumagalli, M. L. Trincavelli, C. Verderio, P. Rosa, D. Lecca, S. Ferrario, C. Parravicini, V. Capra, P. Gelosa, U. Guerrini, S. Belcredito, M. Cimino, L. Sironi, E. Tremoli, G. E. Rovati, C. Martini, M. P. Abbracchio, The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 25, 4615-4627 (2006).
15. Y. Chen, H. Wu, S.Wang, H. Koito, J. Li, F. Ye, J. Hoang, S. S. Escobar, A. Gow, H. A. Arnett, B. D. Trapp, N. J. Karandikar, J. Hsieh, Q. R. Lu, The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. Nat. Neurosci. 12, 1398-1406 (2009).
16. D. Lecca, M. L. Trincavelli, P. Gelosa, L. Sironi, P. Ciana, M. Fumagalli, G. Villa, C. Verderio, C. Grumelli, U. Guerrini, E. Tremoli, P. Rosa, S. Cuboni, C. Martini, A. Buffo, M. Cimino, M. P. Abbracchio, The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One 3, e3579 (2008).
17. M. Fumagalli, S. Daniele, D. Lecca, P. R. Lee, C. Parravicini, R. D. Fields, P. Rosa, F. Antonucci, C. Verderio, M. L. Trincavelli, P. Bramanti, C. Martini, M. P. Abbracchio, Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation. J. Biol. Chem. 286, 10593-10604 (2011).
18. S. Ceruti, F. Viganò, E. Boda, S. Ferrario, G. Magni, M. Boccazzi, P. Rosa, A. Buffo, M. P. Abbracchio, Expression of the new P2Y-like receptor GPR17 during oligodendrocyte precursor cell maturation regulates sensitivity to ATP-induced death. Glia 59, 363-378 (2011).
19. J. A. Nielsen, D. Maric, P. Lau, J. L. Barker, L. D. Hudson, Identification of a novel oligodendrocyte cell adhesion protein using gene expression profiling. J. Neurosci. 26, 9881-9891 (2006).
20. C. E. Heise, B. F. O'Dowd, D. J. Figueroa, N. Sawyer, T. Nguyen, D. S. Im, R. Stocco, J. N. Bellefeuille, M. Abramovitz, R. Cheng, D. L.Williams, Z. Zeng, Q. Liu, L. Ma, M. K. Clements, N. Coulombe, Y. Liu, C. P. Austin, S. R. George, G. P. O'Neill, K. M. Metters, K. R. Lynch, J. F. Evans, Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275, 30531-30536 (2000).
21. 4. Proc. Natl. Acad. Sci. U.S.A. 106, 11685-11690 (2009).
22. 2) receptor. Br. J. Pharmacol. 160, 399-409 (2010).
23. T. Benned-Jensen, M. M. Rosenkilde, Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants. Br. J. Pharmacol. 159, 1092-1105 (2010).
24. A.-D. Qi, T. K. Harden, R. A. Nicholas, Is GPR17 a P2Y/leukotriene receptor? Examination of uracil nucleotides, nucleotide sugars, and cysteinyl leukotrienes as agonists of GPR17. J. Pharmacol. Exp. Ther. 347, 38-46 (2013).
25. R. Schröder, N. Janssen, J. Schmidt, A. Kebig, N. Merten, S. Hennen, A. Müller, S. Blättermann, M. Mohr-Andrä, S. Zahn, J. Wenzel, N. J. Smith, J. Gomeza, C. Drewke, G. Milligan, K. Mohr, E. Kostenis, Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat. Biotechnol. 28, 943-949 (2010).
26. R. Schröder, J. Schmidt, S. Blättermann, L. Peters, N. Janssen, M. Grundmann, W. Seemann, D. Kaufel, N. Merten, C. Drewke, J. Gomeza, G. Milligan, K. Mohr, E. Kostenis, Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat. Protoc. 6, 1748-1760 (2011).
27. A. Bock, N. Merten, R. Schrage, C. Dallanoce, J. Bätz, J. Klöckner, J. Schmitz, C. Matera, K. Simon, A. Kebig, L. Peters, A. Müller, J. Schrobang-Ley, C. Tränkle, C. Hoffmann, M. de Amici, U. Holzgrabe, E. Kostenis, K. Mohr, The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat. Commun. 3, 1044 (2012).
28. E. Verdonk, K. Johnson, R. McGuinness, G. Leung, Y.-W. Chen, H. R. Tang, J. M. Michelotti, V. F. Liu, Cellular dielectric spectroscopy: A label-free comprehensive platform for functional evaluation of endogenous receptors. Assay Drug Dev. Technol. 4, 609-619 (2006).
29. 1 stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: Role of compartmentalized phosphodiesterases. J. Cell Biol. 175, 441-451 (2006).
30. M. Fujioka, S. Koda, Y. Morimoto, K. Biemann, Structure of FR900359, a cyclic depsipeptide from Ardisia crenata sims. J. Org. Chem. 53, 2820-2825 (1988).
31. A. Nesterov, M. Hong, C. Hertel, P. Jiao, L. Brownell, E. Cannon, Screening a plant extract library for inhibitors of cholecystokinin receptor CCK1 pathways. J. Biomol. Screen. 15, 518-527 (2010).
32. I. Eberini, S. Daniele, C. Parravicini, C. Sensi, M. L. Trincavelli, C. Martini, M. P. Abbracchio, In silico identification of new ligands for GPR17: A promising therapeutic target for neurodegenerative diseases. J. Comput. Aided Mol. Des. 25, 743-752 (2011).
33. S. Rajagopal, K. Rajagopal, R. J. Lefkowitz, Teaching old receptors new tricks: Biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386 (2010).
34. E. Reiter, S. Ahn, A. K. Shukla, R. J. Lefkowitz, Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52, 179-197 (2012).
35. T. P. Kenakin, Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat. Rev. Drug Discov. 8, 617-626 (2009).
36. M. Azzi, P. G. Charest, S. Angers, G. Rousseau, T. Kohout, M. Bouvier, G. Piñeyro, β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 100, 11406-11411 (2003).
37. L. M. Luttrell, D. Gesty-Palmer, Beyond desensitization: Physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 62, 305-330 (2010).
38. J. G. Baker, I. P. Hall, S. J. Hill, Agonist and inverse agonist actions of β-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signaling. Mol. Pharmacol. 64, 1357-1369 (2003).
39. K. Rakesh, B. Yoo, I.-M. Kim, N. Salazar, K.-S. Kim, H. A. Rockman, β-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci. Signal. 3, ra46 (2010).
40. M. C. Scimia, C. Hurtado, S. Ray, S. Metzler, K. Wei, J. Wang, C. E. Woods, N. H. Purcell, D. Catalucci, T. Akasaka, O. F. Bueno, G. P. Vlasuk, P. Kaliman, R. Bodmer, L. H. Smith, E. Ashley, M. Mercola, J. H. Brown, P. Ruiz-Lozano, APJ acts as a dual receptor in cardiac hypertrophy. Nature 488, 394-398 (2012).
41. D. M. Rosenbaum, S. G. F. Rasmussen, B. K. Kobilka, The structure and function of G-protein-coupled receptors. Nature 459, 356-363 (2009).
42. T. Kenakin, A. Christopoulos, Signalling bias in new drug discovery: Detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205-216 (2013).
43. J. S. Gutkind, Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci. STKE 2000, re1 (2000).
44. 35S]GTPγS binding and electrophysiological studies in 1321N1 cells. Am. J. Physiol. Cell Physiol. 297, C1028-C1040 (2009).
45. S. J. Charlton, G. Vauquelin, Elusive equilibrium: The challenge of interpreting receptor pharmacology using calcium assays. Br. J. Pharmacol. 161, 1250-1265 (2010).
46. 1 receptor. Nature 399, 789-793 (1999).
47. G. Milligan, Orthologue selectivity and ligand bias: Translating the pharmacology of GPR35. Trends Pharmacol. Sci. 32, 317-325 (2011).
48. A. Strasser, H.-J. Wittmann, A. Buschauer, E. H. Schneider, R. Seifert, Species-dependent activities of G-protein-coupled receptor ligands: Lessons from histamine receptor orthologs. Trends Pharmacol. Sci. 34, 13-32 (2013).
49. 1 receptors after repetitive agonist application. Naunyn. Schmiedebergs Arch. Pharmacol. 371, 466-472 (2005).
50. 13 receptor-type. Br. J. Pharmacol. 141, 141-151 (2004).
51. B. K. Atwood, J. Lopez, J. Wager-Miller, K. Mackie, A. Straiker, Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics 12, 14 (2011).
52. + currents necessary for cell differentiation and stimulates cell migration by activating the GPR17 receptor in oligodendrocyte precursors. Glia 61, 1155-1171 (2013).
53. S. Tucek, P. Michal, V. Vlachová, Modelling the consequences of receptor-G-protein promiscuity. Trends Pharmacol. Sci. 23, 171-176 (2002).
54. R. Bläsius, R. G. Weber, P. Lichter, A. Ogilvie, A novel orphan G protein-coupled receptor primarily expressed in the brain is localized on human chromosomal band 2q21. J. Neurochem. 70, 1357-1365 (1998).
55. J. D. Cahoy, B. Emery, A. Kaushal, L. C. Foo, J. L. Zamanian, K. S. Christopherson, Y. Xing, J. L. Lubischer, P. A. Krieg, S. A. Krupenko, W. J. Thompson, B. A. Barres, A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. J. Neurosci. 28, 264-278 (2008).
56. A. P. Davenport, S. P. H. Alexander, J. L. Sharman, A. J. Pawson, H. E. Benson, A. E. Monaghan, W. C. Liew, C. P. Mpamhanga, T. I. Bonner, R. R. Neubig, J. P. Pin, M. Spedding, A. J. Harmar, International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: Recommendations for new pairings with cognate ligands. Pharmacol. Rev. 65, 967-986 (2013).
57. C. Parravicini, G. Ranghino, M. P. Abbracchio, P. Fantucci, GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors. BMC Bioinformatics 9, 263 (2008).
58. S. Daniele, M. L. Trincavelli, P. Gabelloni, D. Lecca, P. Rosa, M. P. Abbracchio, C. Martini, Agonist-induced desensitization/resensitization of human G protein-coupled receptor 17: A functional cross-talk between purinergic and cysteinyl-leukotriene ligands. J. Pharmacol. Exp. Ther. 338, 559-567 (2011).
59. X. Liang, N. A. Draghi, M. D. Resh, Signaling from integrins to Fyn to Rho family GTPases regulates morphologic differentiation of oligodendrocytes. J. Neurosci. 24, 7140-7149 (2004).
60. G. J. Sturm, R. Schuligoi, E. M. Sturm, J. F. Royer, D. Lang-Loidolt, H. Stammberger, R. Amann, B. A. Peskar, A. Heinemann, 5-Oxo-6,8,11,14- eicosatetraenoic acid is a potent chemoattractant for human basophils. J. Allergy Clin. Immunol. 116, 1014-1019 (2005).
61. E. Kostenis, L. Martini, J. Ellis, M. Waldhoer, A. Heydorn, M. M. Rosenkilde, P. K. Norregaard, R. Jorgensen, J. L. Whistler, G. Milligan, A highly conserved glycine within linker I and the extreme C terminus of G protein α subunits interact cooperatively in switching G protein-coupled receptor-to-effector specificity. J. Pharmacol. Exp. Ther. 313, 78-87 (2005).
62. 2 receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J. Med. Chem. 52, 2762-2775 (2009).
63. Y. Chen, V. Balasubramaniyan, J. Peng, E. C. Hurlock, M. Tallquist, J. Li, Q. R. Lu, Isolation and culture of rat and mouse oligodendrocyte precursor cells. Nat. Protoc. 2, 1044-1051 (2007).
64. J. R. Chan, T. A. Watkins, J. M. Cosgaya, C. Zhang, L. Chen, L. F. Reichardt, E. M. Shooter, B. A. Barres, NGF controls axonal receptivity to myelination by Schwann cells or oligodendrocytes. Neuron 43, 183-191 (2004).
65. F. Marteau, E. Le Poul, D. Communi, D. Communi, C. Labouret, P. Savi, J.-M. Boeynaems, N. S. Gonzalez, Pharmacological characterization of the human P2Y13 receptor. Mol. Pharmacol. 64, 104-112 (2003).
66. 3R) inverse agonists. ChemMedChem 4, 1063-1068 (2009).
67. i and downstream signaling cascade activation. J. Biol. Chem. 284, 1324-1336 (2009).
68. C. Galés, R. V. Rebois, M. Hogue, P. Trieu, A. Breit, T. E. Hébert, M. Bouvier, Real-time monitoring of receptor and G-protein interactions in living cells. Nat. Methods 2, 177-184 (2005).
69. B. Fogal, C. McClaskey, S. Yan, H. Yan, S. A. Rivkees, Diazoxide promotes oligodendrocyte precursor cell proliferation and myelination. PLoS One 5, e10906 (2010).
70. E. Birgbauer, T. S. Rao, M. Webb, Lysolecithin induces demyelination in vitro in a cerebellar slice culture system. J. Neurosci. Res. 78, 157-166 (2004).
71. F. G. Salituro, B. L. Harrison, B. M. Baron, P. L. Nyce, K. T. Stewart, J. H. Kehne, H. S. White, I. A. McDonald, 3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site. J. Med. Chem. 35, 1791-1799 (1992).